R&D Expense--when to remove?

I have a suspicion that in an era of high or --P/Es, we can justify 'some' values by excluding R&D for R&D-specific companies, when a 'valuation' has to be forced

THink of Tesla--sells 1/1000th of the # of cars Ford or Toyota do but is worth more by stock valuations. For years they had negative operating income

If you had to say "this value $ leads to this terminal value" would it be OK to exclude research & development expenses from Operating Expenses?

I understand that's sort of a stretch and this may fluster some academics/good guys but what else should someone do to make a value on a stock where Expense is almost as great or GREATER THAN Gross Margins? :P


Comments (1)

Jan 11, 2022 - 11:53am

Aut voluptatibus nihil corporis autem error perferendis. Nihil pariatur est dignissimos quaerat dignissimos.

Sint iure voluptas saepe atque dolorem cupiditate porro. Ipsum quas modi quo.

Voluptatem enim eveniet nam voluptate molestiae maxime. Eius voluptate inventore debitis. Est non perspiciatis quasi maxime saepe quia adipisci. Natus eligendi dolore non tenetur. Cum adipisci tempora atque maxime ea dicta et est.

Perferendis voluptates tempora soluta dignissimos consequuntur. Dignissimos minima quidem quasi. Quidem in ut nobis. Et excepturi alias praesentium dolor expedita. Minima ea corporis voluptas quas quis. Ut quia qui hic molestiae magni aut.

Start Discussion

Total Avg Compensation

January 2022 Investment Banking

  • Director/MD (6) $2,227
  • Vice President (24) $388
  • Associates (150) $242
  • 2nd Year Analyst (86) $155
  • 3rd+ Year Analyst (15) $150
  • Intern/Summer Associate (65) $144
  • 1st Year Analyst (297) $142
  • Intern/Summer Analyst (226) $90